1 |
BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
|
2 |
HAYASHI T, DESMEULES P, SMITH R S, et al. RASA1 and NF1 are preferentially Co-mutated and define A distinct genetic subset of smoking-associated non-small cell lung carcinomas sensitive to MEK inhibition[J]. Clin Cancer Res, 2018, 24(6): 1436-1447.
|
3 |
CEDILLO J L, BORDAS A, ARNALICH F, et al. Anti-tumoral activity of the human-specific duplicated form of α7-nicotinic receptor subunit in tobacco-induced lung cancer progression[J]. Lung Cancer, 2019, 128: 134-144.
|
4 |
HUANG Y F, LEI L R, LIU Y S. Propofol improves sensitivity of lung cancer cells to cisplatin and its mechanism[J]. Med Sci Monit, 2020, 26: e919786.
|
5 |
HERBST R S, MORGENSZTERN D, BOSHOFF C. The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689): 446-454.
|
6 |
KONG W, LING X, CHEN Y, et al. Hesperetin reverses P‑glycoprotein‑mediated cisplatin resistance in DDP‑resistant human lung cancer cells via modulation of the nuclear factor‑κB signaling pathway[J]. Int J Mol Med, 2020, 45(4): 1213-1224.
|
7 |
LIU J, NARVA S, ZHOU K, et al. A Review on the Antitumor Activity of Various Nitrogenous-based Heterocyclic Compounds as NSCLC Inhibitors[J]. Mini Revi Medi Chemi, 2019, 19(18): 1517.
|
8 |
LIU C, TANG X, LI P, et al. Suberitine A–D, four new cytotoxic dimeric aaptamine alkaloids from the Marine Sponge Aaptos suberitoides[J]. Org Lett, 2012, 14(8): 1994-1997.
|
9 |
AOKI S, KONG D, SUNA H, et al. Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner[J]. Biochem Biophys Res Commun, 2006, 342(1): 101-106.
|
10 |
JIN M H, ZHAO W N, ZHANG Y W, et al. Antiproliferative effect of aaptamine on human chronic myeloid leukemia K562 cells[J]. Int J Mol Sci, 2011, 12(11): 7352-7359.
|
11 |
DYSHLOVOY S A, NAETH I, VENZ S, et al. Proteomic profiling of germ cell cancer cells treated with aaptamine, a marine alkaloid with antiproliferative activity[J]. J Proteome Res, 2012, 11(4): 2316-2330.
|
12 |
DYSHLOVOY S A, VENZ S, SHUBINA L K, et al. Activity of aaptamine and two derivatives, demethyloxyaaptamine and isoaaptamine, in cisplatin-resistant germ cell cancer[J]. J Proteomics, 2014, 96: 223-239.
|
13 |
BOWLING J J, PENNAKA H K, IVEY K, et al. Antiviral and anticancer optimization studies of the DNA-binding marine natural product aaptamine[J]. Chem Biol Drug Des, 2008, 71(3): 205-215.
|
14 |
FUNK F, KRÜGER K, HENNINGER C, et al. Spongean alkaloids protect rat kidney cells against cisplatin-induced cytotoxicity[J]. Anticancer Drugs, 2014, 25(8): 917-929.
|
15 |
CHOU T C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies[J]. Pharmacol Rev, 2006, 58(3): 621-681.
|
16 |
XIAO L, LAN X Y, SHI X P, et al. Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer[J]. Cell Death Dis, 2017, 8(5): e2803.
|
17 |
KIM I K, MCCUTCHEON J N, RAO G H, et al. Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer[J]. Oncogene, 2019, 38(2): 180-193.
|
18 |
张 茂,孙浩言,张 磊.降低miR-21表达对顺铂耐药A549细胞药物敏感性的影响[J]. 郑州大学学报(医学版), 2019,54(3): 422-425.
|
19 |
ZHANG Z Q, GUO X R, TO K K W, et al. Olmutinib (HM61713) reversed multidrug resistance by inhibiting the activity of ATP-binding cassette subfamily G member 2 in vitro and in vivo[J]. Acta Pharm Sin B, 2018, 8(4): 563-574.
|
20 |
ZHANG G N, ZHANG Y K, WANG Y J, et al. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo[J]. Cancer Lett, 2018, 424: 19-29.
|
21 |
KE B, WEI T, HUANG Y Y, et al. Interleukin-7 resensitizes non-small-cell lung cancer to cisplatin via inhibition of ABCG2[J]. Mediators Inflamm, 2019, 2019: 7241418.
|
22 |
TANG Y, HOU J M, LI G H, et al. ABCG2 regulates the pattern of self-renewing divisions in cisplatin-resistant non-small cell lung cancer cell lines[J]. Oncol Rep, 2014, 32(5): 2168-2174.
|
23 |
LIN C Y, HUNG C C, WANG C C N, et al. Demethoxycurcumin sensitizes the response of non-small cell lung cancer to cisplatin through downregulation of TP and ERCC1-related pathways[J]. Phytomedicine, 2019, 53: 28-36.
|
24 |
WANG S, LIU F, ZHU J Y, et al. DNA repair genes ERCC1 and BRCA1 expression in non-small cell lung cancer chemotherapy drug resistance[J]. Med Sci Monit, 2016, 22: 1999-2005.
|
25 |
XIA A Z, LI H H, LI R, et al. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression[J]. Oncol Rep, 2018, 40(4): 2353-2362.
|
26 |
DYSHLOVOY S A, HONECKER F. Marine compounds and cancer: 2017 updates[J]. Mar Drugs, 2018, 16(2):E41.
|
27 |
张善文,黄洪波,桂 春,等. 海洋药物及其研发进展[J]. 中国海洋药物. 2018, 37(3): 77-92.
|